A pivotal Phase III trial of GMI-1271 in Patients With Acute Myeloid Leukemia.

Trial Profile

A pivotal Phase III trial of GMI-1271 in Patients With Acute Myeloid Leukemia.

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs GMI 1271 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors GlycoMimetics
  • Most Recent Events

    • 15 Nov 2017 New trial record
    • 08 Nov 2017 According to a GlycoMimetics media release, company plans to initiate this trial in mid of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top